Kronos Bio, Inc.
KRON · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.01 | 0.07 | 0.02 |
| FCF Yield | -25.60% | -22.40% | -20.50% | -24.26% |
| EV / EBITDA | 2.81 | 0.22 | -0.73 | -1.42 |
| Quality | ||||
| ROIC | -9.09% | -24.14% | -11.13% | -11.64% |
| Gross Margin | 81.33% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.54 | 0.50 | 0.88 | 1.01 |
| Growth | ||||
| Revenue 3-Year CAGR | 95.99% | 2,143,363.11% | 2,144,523.31% | 2,033,579.66% |
| Free Cash Flow Growth | -0.02% | -3.84% | 24.29% | 31.69% |
| Safety | ||||
| Net Debt / EBITDA | 10.97 | 5.60 | 3.21 | 2.53 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -406.03 | -127.77 | -279.39 | -212.14 |